OncoMatch/Clinical Trials/NCT06363006
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
Is NCT06363006 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TKI+Cardunilimab for hepatocellular carcinoma.
Treatment: TKI+Cardunilimab — The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma. The main questions it aims to answer are: * Objective response rate (ORR) for evaluation * Disease Control Rate (DCR); Duration of relief (DoR); Progression free survival (PFS); Total survival time (OS); Safety。
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE C, STAGE B THAT PROGRESSES IRREMEDIABLY AFTER SURGERY AND/OR LOCAL TREATMENT (BCLC)
Barcelona Clinic Liver Cancer (BCLC) stage C; It is not suitable for radical surgery and/or local treatment or stage B that progresses irremediably after surgery and/or local treatment.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic antitumor therapy
Progression or intolerance after receiving at least one systemic antitumor therapy for hepatocellular carcinoma prior to initial administration
Cannot have received: liver transplantation
History of liver transplantation.
Lab requirements
Liver function
child-pugh level a
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify